ZORYVE (Roflumilast) Use During Pregnancy
ZORYVE cream should generally be avoided during pregnancy due to insufficient human safety data and concerning animal reproduction findings, though no structural birth defects were observed in animal studies at high doses.
Key Safety Information from FDA Labeling
The FDA label for ZORYVE provides critical pregnancy-related data 1:
Insufficient human data: There are no adequate studies in pregnant women to establish safety for major birth defects, miscarriage, or other adverse maternal/fetal outcomes 1
Animal reproduction findings at high systemic doses (well above typical topical exposure):
Clinical Considerations
Labor and delivery: The FDA specifically recommends avoiding ZORYVE during labor and delivery, as animal studies showed roflumilast disrupted the labor/delivery process in mice 1
Risk-benefit assessment: The background risk of major birth defects (2-4%) and miscarriage (15-20%) in the U.S. general population should be weighed against the limited human safety data 1
Practical Approach
If pregnancy is recognized: Discontinue ZORYVE and consider alternative treatments with better-established pregnancy safety profiles 1
Women of childbearing potential: Counsel about the limited pregnancy data before initiating therapy 1
Topical exposure considerations: While topical medications generally have lower systemic absorption than oral formulations 2, the specific absorption and fetal exposure with ZORYVE cream remains incompletely characterized
Important Caveats
The animal toxicity data involved oral dosing at multiples far exceeding typical human topical exposure 1. However, the absence of human pregnancy data and the FDA's specific recommendation to avoid use during labor/delivery support a cautious approach 1.